Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

842 Features
Advanced Forum on IPR in CHINA

09 Aug 06

The protection of intellectual property (IP) rights has become crucial to the success of many foreign investors and enterprises who wish to profit from China’s fast growing market. As many foreign investors have discovered that counterfeiting, passing off and other forms of IP infringement are common in China. At the same time, Chinese companies are investing heavily in sophisticated technology and require an effective IP system to protect their own investment. The dynamics of protecting inte
Jones Days

Candidate Profile: Paul Collins

09 Aug 06

Candidate Profile: Paul Collins Current Job Title: Clinical Project Manager II Department: Clinical Commenced with ICON: July 1997
Mike Wood, Freya Eden-Ellis

Movers and Shakers of the Pharma Industry - Andy Sarfas

08 Aug 06

Andy Sarfas is our mover and shaker of the week. He is the Global Internet Business Manager for Reckitt Benckiser.
Freya Eden-Ellis

Movers and Shakers of the Pharma Industry - David Mitchell

08 Aug 06

David Mitchell is the Commercial Director at McNeil Consumer Healthcare, a company that produces remedies for self-treatment available at pharmacies and supermarket stores.
Freya Eden-Ellis

Movers and Shakers of the Pharma Industry - Alex Bishop

08 Aug 06

Alex Bishop is the IT Business Manager at Pfizer, the largest supplier of medicines to the NHS.
Freya Eden-Ellis

Diverse challenges await generics industry

04 Aug 06

Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.
Datamonitor

Lean Documentation 4

03 Aug 06

Manufacturing Instructions and Records: Operators are expected to follow manufacturing instructions to produce a product that meets the required specification. Typically these instructions will be written by technical experts, the chemical engineers who were responsible for the technology transfer, the process validation and so on.
PharmiWeb.com Field Reporter: Joanna Hills

Networking Tips

03 Aug 06

Networking: What is it and How do you do it?
Jim Melling - Field Reporter

Preparing for GCP Inspections: The Truth, the Whole Truth, and Nothing But the Truth

02 Aug 06

Every sponsor or CRO can expect their country’s regulatory agency to arrive on their premises periodically to conduct routine inspections. In the UK, for instance, the Medicines and Healthcare products Regulatory Agency (MHRA) conducts routine periodic inspections approximately every three years. Apart from these, the MHRA also conducts “for cause” and “follow up” inspections, and they also take part in the third-country inspection program. Because all inspections may be either announced or unan
Triona Coll

Call for guidelines on when to stop or continue drug treatment for Alzheimer’s Disease

01 Aug 06

Doctors taking part in a survey on Alzheimer’s Disease (AD) management have called for clear and consistent guidelines on diagnosis and treatment of the condition to be drawn up as a matter of urgency. The survey was sponsored by Eisai Europe Ltd and Pfizer Inc, who market the cholinesterase inhibitor Aricept (donepezil), and was presented during the International Conference on Alzheimer’s Disease and Related Disorders.
Olwen Glynn Owen – Pharmiweb Field Reporter

A Full Pipeline of Follow-on TNF-Antagonists

01 Aug 06

The US$ 7.6 bln market of TNF-antagonists attracts numerous follow-on compounds including improved TNF-antagonists and molecules originating from new technologies
La Merie Business Intelligence

Sheltering under an Umbrella?

31 Jul 06

The Treasury is aware of a growing trend, which has recently moved into the pharmaceutical sector, for staff to be provided to clients through “umbrella” or “composite” companies. These companies promise a golden scenario of reduced costs to their clients and greater take-home pay to the individuals who work through them.
Claire Jackaman

Antiarrhythmics: RSD1235 woes reduce market potential but not clinical impact

31 Jul 06

Atrial fibrillation (AF) is the most common form of arrhythmia, or irregular heartbeat, with an estimated nine million sufferers worldwide. Although safe, effective treatment for AF is critical, historically there has been little R&D investment and little innovation in the AF market. However, this may be about to change, with the AF market expected to triple by 2015.
Datamonitor

New Tools for Mental Health Professionals: Computerised Cognitive Behavioural Therapy (CCBT) in Primary Care

25 Jul 06

Cognitive behaviour therapy (CBT) combines two very effective kinds of psychotherapy delivered face to face by medical therapists
Jim Melling - PharmiWeb Field Reporter

Lean Documentation 2b

25 Jul 06

In the last report we analysed part of an SOP control system for inefficiencies and opportunities for error, by mapping the system and asking ‘what if?’ at each stage. But, as we mentioned previously, documentation systems (or, indeed, any type of control system) rarely operate in isolation. So let’s look at some of the inputs and outputs there might be on a typical site, using the same process as before.
Joanna Hills - PharmiWeb Field Reporter

Lean Documentation 2

25 Jul 06

A well-run documentation system will support your business processes and improvements, not hold them back. How do you ensure that this is the case?
Joanna Hills - PharmiWeb Field Reporter

PowderMed: flying ahead in avian flu

21 Jul 06

PowderMed has submitted an application to UK regulators seeking to conduct human trials of its avian influenza vaccine. Developing an effective vaccine against the next influenza pandemic is a challenging task, but one many companies are taking on. However, until a virus able to cause a pandemic emerges, no one knows for certain which product will be most effective.
Datamonitor

Role of Arenesp and cinacalcet in protecting hearts of renal patients

20 Jul 06

Treatment of chronic kidney disease (CKD) is focussing increasingly on prevention of cardiovascular complications with the aim of reducing the cardiovascular mortality and morbidity to which many patients currently succumb.
Olwen Glynn Owen - PharmiWeb Field Reporter

Hints and Tips: Survive in the Work Place Part Two

19 Jul 06

Hints and Tips: Survive in the Work Place Part Two
Elaine Ford - PharmiWeb Field Reporter

Generic Pharmaceutical Patent Searching

13 Jul 06

'Drug In Focus' is written by Leighton Howard, a patent information expert with extensive generics experience. He has worked within the professional patent information industry and major generic pharmaceutical firms and now provides consultancy services to the generics industry and government organisations via his company XIP Pty Ltd. He is also the founder of GenericsWeb and remains instrumental in maintaining the high quality and accuracy of data contained in Pipeline Patent Intelligence.
Leighton Howard

Urinary incontinence: common problem, not commonly reported

13 Jul 06

Despite not being a widely acknowledged affliction, urinary incontinence (UI) is a relatively common condition, with up to 23% of the female population suffering from one form alone. Yet despite the significant impact UI can have on the quality of life of the sufferers, according to a new report, approximately half of sufferers neither seek treatment nor report the problem to a physician.
Datamonitor

New data results for Roche cancer drug Xeloda impressive

10 Jul 06

ROCHE is set to file for a new indication for its oral, targeted cancer drug Xeloda® following impressive new data presented at the American Society of Clinical Oncology conference (ASCO).
Rhonda Siddall,

Lean Documentation 1: GLP, GCP, GMP, SOP, too many documents ?

09 Jul 06

Pharmaceutical companies are renowned for exhaustive pages of regulatory reports and documentation procedures. An enormous amount of effort goes into creating and maintaining these documentations, usually by people for whom it is only a small part of their job. Another problem is that complexity exists in such documents and may be due to an excess of information or to inappropriate structure. Again, historically there may have been a drive to put every little detail into the procedures, in t
PharmiWeb Field Reporter -Joanna Hills

Biomarin advance novel antihypertensive...Researchers identify novel molecular target for the treatment of sepsis

07 Jul 06

Todays Headlines from across the DailyUpdates network (July 7th, 2006) - In today's edition we highlight Biomarin's development of the novel antihypertensive 6R-BH4 and new research describing a promising molecular target for future sepsis therapeutics.
LeadDiscovery

Phase 2 testing commences on Abiogen's anxiolytic ABIO 0801...Novel drug delivery technology facilitating the use of therapeutic macromolecules

05 Jul 06

Todays Headlines from across the DailyUpdates network (from DailyUpdates 5th July)- Although press releases are quite thin on the ground today because of the July 4th holiday in the US, Abiogen have released important information regarding the start of phase 2 testing of the company's anxiolytic, ABIO 08/01. In addition we feature a review describing a potentially groundbreaking drug delivery technology. This technology harnesses protein transduction domains (PTDs), endogenous peptide sequences
LeadDiscovery

Biologics driving growth to 2010

29 Jun 06

The leading pharmaceutical companies have historically focused on developing small molecules to drive their bottom line growth. However, this is set to change, with around 60% of revenue growth for 'Big Pharma' companies forecast to come from biologic products. In fact by 2010, annual sales of biologics will have increased by $26 billion, compared to a $13 billion increase for small molecules.
Datamonitor

New clinical data on Vasogen's heart failure candidate...Johnson and Johnson publish on potential asthma candidate

27 Jun 06

Todays Headlines from across the DailyUpdates network - Today we feature news from Vasogen on their candidate treatment of chronic heart failure plus new data from Johnson & Johnson on a new integrin antagonist that may underly a future treatment of asthma
LeadDiscovery

ArQule moves forward with their cell cycle modulator...Wyeth develops selective GABA(A) alpha2/alpha3 subtype agonists as candidate anxiolytics

21 Jun 06

Todays Headlines from across the DailyUpdates network (20th June, 2006): We highlight research from Merck who are developing a novel approach to anxiety and news from ArQule on their oncology candidate
LeadDiscovery

Micromet develops new lymphoma therapeutic...KD-247, a promising HIV-neutralizing antibody

20 Jun 06

Todays Headlines from across the DailyUpdates network (19th June - 2006): Today we feature over 60 breaking journal articles including our featured study discussing the development of a new antibody being developed for HIV-1. In addition we highlight news from Micromet on their antibody therapy for the treatment of NHL
LeadDiscovery

Biogenerics and new technologies compete with 1st generation major protein products

19 Jun 06

The US$ 32 bln market of six major protein products is enfacing competition by less costly biogenerics and by improved products via drug delivery or protein engineering technologies and even oral, small molecule solutions
La Merie Business Intelligence

Advertising